Form 4: Milton C. Ault III Reports Purchase and Disposal of Alzamend Neuro Shares

Milton C. Ault III, a director and 10% owner of Alzamend Neuro, Inc., reported purchasing 1,000 shares and disposing of 166,865 shares of common stock on April 19, 2024.

Summary

• On April 19, 2024, Milton C. Ault III, a director and 10% owner of Alzamend Neuro, Inc., engaged in transactions involving the company's common stock.
• Ault purchased 1,000 shares at a weighted average price of $0.6882, with prices ranging from $0.6819 to $0.6895 per share.
• He also disposed of 166,865 shares.
• Following these transactions, Ault directly owns no shares, but indirectly owns 771,699 shares through Ault Lending, LLC, 996,197 shares through Ault Life Sciences, Inc., and 5,498 shares through Ault Life Sciences Fund, LLC.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there's a purchase of 1,000 shares, the disposal of 166,865 shares balances it out. The market's reaction will depend on how they interpret the insider's actions.

Negatives

• The disposal of 166,865 shares by a director and 10% owner could be interpreted negatively by the market.

Risks

• The Form 4 filing indicates potential changes in Ault's investment strategy regarding Alzamend Neuro, which could influence investor sentiment.
• The indirect ownership structure adds complexity to assessing Ault's overall stake and influence.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge insider sentiment and potential future stock performance.

Stakeholder Impact

• Shareholders may react to the reported transactions, potentially influencing the stock price.
• The transactions could affect investor confidence depending on their interpretation of the insider's actions.

Key Dates

Keywords

Alzamend Neuro, ALZN, Milton C. Ault III, Form 4, Beneficial Ownership, Stock Transactions, Ault Lending, Ault Life Sciences